These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9157606)

  • 1. Impact of factor V Leiden mutation on duration of anticoagulation after a single thromboembolic event.
    Rintelen C; Pabinger I; Lechner K; Mannhalter C
    Thromb Haemost; 1997 Feb; 77(2):405. PubMed ID: 9157606
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor V Leiden and recurrent venous thromboembolism.
    Ridker PM
    Thromb Haemost; 1996 Nov; 76(5):815-6. PubMed ID: 8950797
    [No Abstract]   [Full Text] [Related]  

  • 3. Thromboembolic risk assessment in a phenotypically cured factor-V-Leiden carrier after orthotopic liver transplantation.
    Strobel J; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2010; 56(5-6):245-7. PubMed ID: 20575473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid detection of factor V Leiden (FVQ506) by non-radioactive single strand conformation polymorphism (SSCP).
    Arruda VR; von Zuben PM; Annichino-Bizzachi JM; Costa FF
    Sangre (Barc); 1996 Oct; 41(5):379-81. PubMed ID: 8986114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
    Schambeck CM; Eberl E; Geisen U; Grossmann R; Keller F
    Thromb Haemost; 2001 May; 85(5):782-6. PubMed ID: 11372668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: importance of synergistic factors.
    Page C; Rubin LE; Gusberg RJ; Dardik A
    J Vasc Surg; 2005 Nov; 42(5):1014-8. PubMed ID: 16275464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.
    Hoagland LE; Triplett DA; Peng F; Barna L
    Thromb Res; 1996 Sep; 83(5):363-73. PubMed ID: 8873345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of factor V Leiden in surgical patients with symptomatic venous thromboembolism despite prophylaxis.
    Baba-Ahmed M; Le Gal G; Couturaud F; Lacut K; Oger E; Leroyer C
    Thromb Haemost; 2007 Feb; 97(2):171-5. PubMed ID: 17264942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency.
    Zehnder JL; Jain M
    Blood Coagul Fibrinolysis; 1996 Apr; 7(3):361-2. PubMed ID: 8735145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.
    Marchetti M; Pistorio A; Barosi G
    Thromb Haemost; 2000 Nov; 84(5):752-7. PubMed ID: 11127850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation may be beneficial in high risk factor V Leiden carriers.
    Baglin T; Baglin C; Brown K; Luddington R
    BMJ; 1998 Aug; 317(7155):416. PubMed ID: 9694774
    [No Abstract]   [Full Text] [Related]  

  • 12. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
    Dizon-Townson D; Miller C; Sibai B; Spong CY; Thom E; Wendel G; Wenstrom K; Samuels P; Cotroneo MA; Moawad A; Sorokin Y; Meis P; Miodovnik M; O'Sullivan MJ; Conway D; Wapner RJ; Gabbe SG;
    Obstet Gynecol; 2005 Sep; 106(3):517-24. PubMed ID: 16135581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of thrombophilia in deciding on the duration of anticoagulation.
    Bauer KA
    Semin Thromb Hemost; 2004 Dec; 30(6):633-7. PubMed ID: 15630669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Factor V Leiden mutation. Successful outcome of a pregnancy after heparin therapy].
    Mazzarella CR; Del Bianco A; Pietropaolo F
    Minerva Ginecol; 2003 Feb; 55(1):81-5. PubMed ID: 12598848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
    Santamaria MG; Agnelli G; Taliani MR; Prandoni P; Moia M; Bazzan M; Guazzaloca G; Ageno W; Bertoldi A; Silingardi M; Tomasi C; Ambrosio GB;
    Thromb Res; 2005; 116(4):301-6. PubMed ID: 16038714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of factor V deficiency with factor V HR2.
    Faioni EM; Castaman G; Asti D; Lussana F; Rodeghiero F
    Haematologica; 2004 Feb; 89(2):195-200. PubMed ID: 15003895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended treatment for venous thromboembolism: how long is long enough?
    Cosmi B; Palareti G
    Curr Hematol Rep; 2004 Sep; 3(5):375-81. PubMed ID: 15341706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma resistance to activated protein C in venous and arterial thrombosis.
    Cushman M; Bhushan F; Bovill E; Tracy R
    Thromb Haemost; 1994 Oct; 72(4):647. PubMed ID: 7878648
    [No Abstract]   [Full Text] [Related]  

  • 20. Coagulation, anticoagulation and pancreatic carcinoma.
    Nakchbandi IA; Löhr JM
    Nat Clin Pract Gastroenterol Hepatol; 2008 Aug; 5(8):445-55. PubMed ID: 18594494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.